Gary S. Hogge - Mar 9, 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
SVP,Clinical & Medical Affairs
Signature
/s/ Grant Harbert, as Attorney-in Fact
Stock symbol
LCTX
Transactions as of
Mar 9, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 06:06 PM
Previous filing
Feb 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (right to buy) Award $0 +400K $0.00 400K Mar 9, 2023 Common Shares 400K $1.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.